poisar

Stocks · News reference

Regeneron Pharmaceuticals Q2 Adj. EPS $14.29 Beats $10.26 Estimate, Sales $4.291B Beat $3.816B Estimate

Jul 30, 2026, 10:30 AMBenzinga Newsdesk

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat the analyst consensus estimate of $10.26 by 39.28 percent. This is a 10.86 percent increase over earnings of $12.89 per

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGN
Source
benzinga
Observed
Jul 30, 2026, 10:30 AM
Checked
Jul 30, 2026, 10:29 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool
    AMGNVRTXREGN